PT879056E - Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados - Google Patents

Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados

Info

Publication number
PT879056E
PT879056E PT97904765T PT97904765T PT879056E PT 879056 E PT879056 E PT 879056E PT 97904765 T PT97904765 T PT 97904765T PT 97904765 T PT97904765 T PT 97904765T PT 879056 E PT879056 E PT 879056E
Authority
PT
Portugal
Prior art keywords
ribavirin
modification
ribavirin3
activated lymphocytes
mediated
Prior art date
Application number
PT97904765T
Other languages
English (en)
Inventor
Robert Tam
Kandsamy Ramasamy
Devron Averett
Original Assignee
Ribapharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26712784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT879056(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/590,449 external-priority patent/US5767097A/en
Application filed by Ribapharm Inc filed Critical Ribapharm Inc
Publication of PT879056E publication Critical patent/PT879056E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/052—Imidazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PT97904765T 1996-01-23 1997-01-21 Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados PT879056E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/590,449 US5767097A (en) 1996-01-23 1996-01-23 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US3609497P 1997-01-17 1997-01-17

Publications (1)

Publication Number Publication Date
PT879056E true PT879056E (pt) 2002-10-31

Family

ID=26712784

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97904765T PT879056E (pt) 1996-01-23 1997-01-21 Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados

Country Status (21)

Country Link
EP (1) EP0879056B1 (pt)
KR (1) KR100298158B1 (pt)
CN (1) CN1190198C (pt)
AT (1) ATE216886T1 (pt)
BR (1) BR9707154A (pt)
CA (1) CA2246162C (pt)
CZ (1) CZ293584B6 (pt)
DE (1) DE69712316T2 (pt)
DK (1) DK0879056T3 (pt)
ES (1) ES2172764T3 (pt)
HU (1) HU220105B (pt)
IL (1) IL125088A0 (pt)
NO (1) NO983372L (pt)
NZ (1) NZ330784A (pt)
PL (1) PL187439B1 (pt)
PT (1) PT879056E (pt)
RU (1) RU2186569C2 (pt)
SI (1) SI9720013A (pt)
SK (1) SK283342B6 (pt)
UA (1) UA46815C2 (pt)
WO (1) WO1997026883A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132393B1 (en) * 1996-10-16 2003-04-09 ICN Pharmaceuticals, Inc. L-Ribavirin and uses thereof
WO1998017279A1 (en) 1996-10-25 1998-04-30 Minnesota Mining And Manufacturing Company Immune response modifier compounds for treatment of th2 mediated and related diseases
BR9917090A (pt) * 1999-01-29 2001-10-16 Icn Pharmaceuticals Modulação de resposta imune por ribavirina
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
ATE517184T1 (de) 2000-08-17 2011-08-15 Tripep Ab Hcv ns3/4a kodierende nukleinsäure
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
JP2006524227A (ja) * 2003-03-28 2006-10-26 ファーマセット，インク． フラビウイルス科ウイルス感染の治療のための化合物
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
RU2451523C2 (ru) 2005-12-14 2012-05-27 Цитос Биотехнологи Аг Упакованные иммуностимулирующей нуклеиновой кислотой частицы, предназначенные для лечения гиперчувствительности
ZA200806266B (en) * 2006-03-09 2010-05-26 Om Pharma Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines
WO2007144150A1 (en) 2006-06-12 2007-12-21 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
SG10201913554YA (en) 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
AU2013361200A1 (en) 2012-12-21 2015-07-23 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201524990A (zh) 2013-10-11 2015-07-01 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE221379T1 (de) * 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen

Also Published As

Publication number Publication date
KR19990081930A (ko) 1999-11-15
AU700642B2 (en) 1999-01-14
AU1747897A (en) 1997-08-20
PL328003A1 (en) 1999-01-04
SK283342B6 (sk) 2003-06-03
CN1209747A (zh) 1999-03-03
CA2246162A1 (en) 1997-07-31
NO983372L (no) 1998-09-21
SK100498A3 (en) 2001-03-12
WO1997026883A1 (en) 1997-07-31
EP0879056A4 (en) 1999-01-13
ATE216886T1 (de) 2002-05-15
CZ293584B6 (cs) 2004-06-16
CA2246162C (en) 2000-04-04
DK0879056T3 (da) 2002-08-19
NO983372D0 (no) 1998-07-22
EP0879056B1 (en) 2002-05-02
NZ330784A (en) 1999-02-25
CN1190198C (zh) 2005-02-23
CZ232998A3 (cs) 1999-04-14
KR100298158B1 (ko) 2001-09-06
SI9720013A (sl) 1999-06-30
HUP9900681A3 (en) 1999-12-28
DE69712316T2 (de) 2003-01-02
DE69712316D1 (en) 2002-06-06
RU2186569C2 (ru) 2002-08-10
IL125088A0 (en) 1999-01-26
ES2172764T3 (es) 2002-10-01
UA46815C2 (uk) 2002-06-17
PL187439B1 (pl) 2004-07-30
BR9707154A (pt) 1999-05-25
HUP9900681A2 (hu) 1999-07-28
EP0879056A1 (en) 1998-11-25
HU220105B (hu) 2001-10-28

Similar Documents

Publication Publication Date Title
PT879056E (pt) Modulacao da expressao das citocinas th1/th2 atraves de ribavirina em linfocitos t activados
ATE49126T1 (de) Mittel zur transdermalen applikation von arzneistoffen.
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
ATE113650T1 (de) Ausgewählte stämme von lactobacillus enthaltende pharmazeutische zusammensetzungen.
DE59007178D1 (de) Verwendung alkylierter Polyethylenimine als gallensäureadsorbierende Arzneimittel sowie pharmazeutische Präparate.
DE3682457D1 (de) Geraet zur verabreichung von medikamenten an patienten.
EP0219076A3 (en) Sustained release composition
DK162986D0 (da) Terapeutisk middel i enhedsdosisform
NO870772L (no) Vevplasminogenaktivator for normale humane tykktarmceller.
FR2643557B1 (fr) Utilisation de n-acylcysteines dans le traitement de maladies associees aux infections par hiv
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
DE68908117D1 (de) N-acetylglukosamin als zytoprotektives mittel.
ATE262346T1 (de) C-c chemokine die die infektion mit retoviren verhindern
ES2098316T3 (es) Procedimiento de purificacion de carrageninas comerciales.
EP1240899A3 (en) Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
EP1174141A3 (en) Modulation of TH1/TH2 cytokine expression by ribavirin and ribavirin analogs in activated t-lymphocytes
SU1473139A1 (ru) Средство, повышающее общую устойчивость организма
FR2599974B1 (fr) Utilisation de la phospholipase a2, association et composition therapeutiques en resultant
UA28284A (uk) Природний лікувальний засіб (його варіанти)